# MAGEA2

## Overview
MAGEA2 is a gene that encodes the protein MAGE family member A2, which is part of the melanoma antigen gene family. This protein is primarily involved in the regulation of cellular processes through its interaction with key proteins such as p53, a critical regulator of the cell cycle and apoptosis. MAGEA2 is categorized as a nuclear protein due to its localization and function within the cell nucleus, where it modulates the activity of p53 by affecting its acetylation and transcriptional activity. This modulation has significant implications for cell cycle control, stress responses, and apoptosis, particularly in the context of cancer. MAGEA2's interactions with other proteins, such as histone deacetylase 3 (HDAC3) and promyelocytic leukemia (PML) proteins, further underscore its role in influencing cellular senescence and proliferation. The gene's expression is notably upregulated in various cancers, including breast, bladder, and lung cancers, where it is associated with tumor progression and treatment resistance, making it a potential marker for poor prognosis (Wong2014Identification; Poojary2020Prognostic; Peche2011MageA2).

## Function
MAGEA2, a member of the melanoma antigen gene family, plays a significant role in cellular processes by interacting with the p53 protein, a crucial regulator of the cell cycle and apoptosis. In healthy human cells, MAGEA2 modulates the function of p53 by impairing its acetylation at promyelocytic leukemia (PML) nuclear bodies, which is essential for p53's stabilization and activation. This interaction reduces p53's transcriptional activity, thereby influencing cell cycle control and stress responses (Peche2011MageA2). MAGEA2 also affects the formation and function of PML nuclear bodies by altering the post-translational modifications of PML proteins, such as sumoylation, which is critical for their proper structure and function (Peche2011MageA2).

MAGEA2's activity is primarily localized to the nucleus, where it interacts with histone deacetylase 3 (HDAC3) to repress p53-dependent apoptosis, particularly in response to stressors like chemotherapeutic drugs (Peche2011MageA2). By modulating these molecular pathways, MAGEA2 influences cellular senescence and proliferation, potentially affecting organismal outcomes related to cell growth and survival (Peche2011MageA2).

## Clinical Significance
MAGEA2 is implicated in the development of tamoxifen-resistant breast cancer. Its expression is upregulated in tamoxifen-resistant tumor cells, where it localizes to the nucleus and forms complexes with p53 and estrogen receptor α (ERα). This interaction leads to the repression of the p53 pathway and increased ER-dependent signaling, contributing to the continued proliferation of breast cancer cells despite tamoxifen treatment (Wong2014Identification). Clinically, MAGEA2 expression is associated with reduced overall survival in ER-positive breast cancer patients treated with tamoxifen, indicating its potential as a marker for poor prognosis (Wong2014Identification).

MAGEA2 also plays a role in other cancers. It is involved in tumorigenesis by enhancing the activity of E3 RING ubiquitin ligases, leading to the degradation of tumor suppressor proteins like p53. This contributes to tumor growth, proliferation, and inhibition of apoptosis (Poojary2020Prognostic). In bladder cancer, MAGEA2 shows stage-dependent expression, with higher levels associated with more advanced stages, suggesting its role in cancer progression (Verma2024Melanoma). The overexpression of MAGEA2 is linked to poor prognosis in several cancers, including lung, ovarian, and pancreatic cancers (Poojary2020Prognostic).

## Interactions
MAGEA2 interacts with several proteins, influencing various cellular processes. It forms complexes with histone deacetylases (HDACs), particularly HDAC3, which leads to the repression of p53 transcriptional activity. This interaction involves the recruitment of HDAC3 to p53-binding sites, resulting in hypoacetylation of p53 and histones, thereby reducing p53's transcriptional activity (Ladelfa2012Tumorspecific; Peche2011MageA2). MAGEA2 also interacts with the promyelocytic leukemia (PML) protein, specifically PMLIV, affecting its acetylation and sumoylation. This interaction impairs the formation of PML nuclear bodies (PML-NBs) and reduces p53 acetylation, which is crucial for p53 stabilization and activation (Peche2011MageA2).

In the context of breast cancer, MAGEA2 forms complexes with p53 and estrogen receptor-α (ERα), leading to the repression of the p53 pathway and enhancement of ER-dependent signaling. This interaction is significant in tamoxifen-resistant breast cancer cells, where MAGEA2's presence correlates with reduced levels of acetylated p53 and increased ERα transcriptional activity (Wong2014Identification). These interactions suggest that MAGEA2 plays a role in modulating key signaling pathways involved in cancer progression and treatment resistance.


## References


[1. (Wong2014Identification) P-P Wong, C C Yeoh, A S Ahmad, C Chelala, C Gillett, V Speirs, J L Jones, and H C Hurst. Identification of magea antigens as causal players in the development of tamoxifen-resistant breast cancer. Oncogene, 33(37):4579–4588, March 2014. URL: http://dx.doi.org/10.1038/onc.2014.45, doi:10.1038/onc.2014.45. This article has 34 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/onc.2014.45)

[2. (Ladelfa2012Tumorspecific) María Fátima Ladelfa, Leticia Yamila Peche, María Fernanda Toledo, Julieta Eva Laiseca, Claudio Schneider, and Martín Monte. Tumor-specific mage proteins as regulators of p53 function. Cancer Letters, 325(1):11–17, December 2012. URL: http://dx.doi.org/10.1016/j.canlet.2012.05.031, doi:10.1016/j.canlet.2012.05.031. This article has 33 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.canlet.2012.05.031)

[3. (Poojary2020Prognostic) Manish Poojary, Padacherri Vethil Jishnu, and Shama Prasada Kabekkodu. Prognostic value of melanoma-associated antigen-a (mage-a) gene expression in various human cancers: a systematic review and meta-analysis of 7428 patients and 44 studies. Molecular Diagnosis &amp; Therapy, 24(5):537–555, June 2020. URL: http://dx.doi.org/10.1007/s40291-020-00476-5, doi:10.1007/s40291-020-00476-5. This article has 20 citations.](https://doi.org/10.1007/s40291-020-00476-5)

[4. (Peche2011MageA2) L Y Peche, M Scolz, M F Ladelfa, M Monte, and C Schneider. Magea2 restrains cellular senescence by targeting the function of pmliv/p53 axis at the pml-nbs. Cell Death &amp; Differentiation, 19(6):926–936, November 2011. URL: http://dx.doi.org/10.1038/cdd.2011.173, doi:10.1038/cdd.2011.173. This article has 42 citations.](https://doi.org/10.1038/cdd.2011.173)

[5. (Verma2024Melanoma) Shiv Verma, Diya Swain, Prem Prakash Kushwaha, Smit Brahmbhatt, Karishma Gupta, Debasish Sundi, and Sanjay Gupta. Melanoma antigen family a (mage a) as promising biomarkers and therapeutic targets in bladder cancer. Cancers, 16(2):246, January 2024. URL: http://dx.doi.org/10.3390/cancers16020246, doi:10.3390/cancers16020246. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers16020246)